PLoS Neglected Tropical Diseases (Sep 2021)

Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi.

  • Leroy Versteeg,
  • Rakesh Adhikari,
  • Cristina Poveda,
  • Maria Jose Villar-Mondragon,
  • Kathryn M Jones,
  • Peter J Hotez,
  • Maria Elena Bottazzi,
  • Edwin Tijhaar,
  • Jeroen Pollet

DOI
https://doi.org/10.1371/journal.pntd.0009689
Journal volume & issue
Vol. 15, no. 9
p. e0009689

Abstract

Read online

Tc24-C4, a modified recombinant flagellar calcium-binding protein of Trypanosoma cruzi, is under development as a therapeutic subunit vaccine candidate to prevent or delay progression of chronic Chagasic cardiomyopathy. When combined with Toll-like receptor agonists, Tc24-C4 immunization reduces parasitemia, parasites in cardiac tissue, and cardiac fibrosis and inflammation in animal models. To support further research on the vaccine candidate and its mechanism of action, murine monoclonal antibodies (mAbs) against Tc24-C4 were generated. Here, we report new findings made with mAb Tc24-C4/884 that detects Tc24-WT and Tc24-C4, as well as native Tc24 in T. cruzi on ELISA, western blots, and different imaging techniques. Surprisingly, detection of Tc24 by Tc24-C/884 in fixed T. cruzi trypomastigotes required permeabilization of the parasite, revealing that Tc24 is not exposed on the surface of T. cruzi, making a direct role of antibodies in the induced protection after Tc24-C4 immunization less likely. We further observed that after immunostaining T. cruzi-infected cells with mAb Tc24-C4/884, the expression of Tc24 decreases significantly when T. cruzi trypomastigotes enter host cells and transform into amastigotes. However, Tc24 is then upregulated in association with parasite flagellar growth linked to re-transformation into the trypomastigote form, prior to host cellular escape. These observations are discussed in the context of potential mechanisms of vaccine immunity.